HC Wainwright Predicts Higher Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Research analysts at HC Wainwright increased their Q3 2025 EPS estimates for shares of Sensus Healthcare in a research note issued on Monday, November 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.08 for the quarter, up from their previous forecast of $0.03. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q4 2025 earnings at $0.20 EPS.

Separately, Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday, November 15th.

Sensus Healthcare Trading Up 9.0 %

NASDAQ SRTS traded up $0.75 during mid-day trading on Wednesday, hitting $9.11. The company's stock had a trading volume of 367,468 shares, compared to its average volume of 279,331. The company's 50 day simple moving average is $6.47 and its 200 day simple moving average is $6.03. Sensus Healthcare has a twelve month low of $2.05 and a twelve month high of $9.20. The firm has a market capitalization of $149.31 million, a price-to-earnings ratio of 15.60 and a beta of 1.04.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in shares of Sensus Healthcare by 34.4% during the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company's stock valued at $2,087,000 after buying an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Sensus Healthcare by 128.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company's stock worth $888,000 after purchasing an additional 93,511 shares during the period. Geode Capital Management LLC raised its position in Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock valued at $849,000 after purchasing an additional 11,525 shares in the last quarter. Sachetta LLC grew its stake in Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company's stock worth $631,000 after buying an additional 13,544 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in Sensus Healthcare by 152.4% during the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company's stock worth $412,000 after buying an additional 46,732 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.